-
Manufacturing, Supply Chain & Infrastructure2 months agoEchocardiographic changes and vascular dysfunction in male and female Fabry patients
Fabry disease has long been recognized as one of medicine’s most insidious inherited disorders, a rare X-linked lysosomal storage condition in which the body’s cellular recycling...
-
Manufacturing, Supply Chain & Infrastructure2 months agoPig to human kidney transplantation hits a new milestone
A pig kidney transplanted into a human patient has broken records by lasting for nine months, buying time until a human donor organ became available.
-
Manufacturing, Supply Chain & Infrastructure2 months agoWatchmaker Genomics Boosts Manufacturing Capacity with Major Boulder Campus Expansion
The Flatiron Park facility in Colorado will serve as the Watchmaker Boulder Manufacturing Center of Excellence for reagent manufacturing and will house the company’s manufacturing, quality,...
-
Manufacturing, Supply Chain & Infrastructure2 months agoUS to grant up to $125M for personalized RNA manufacturing innovation
A new program from ARPA-H has devoted funding to make individualized RNA-based genetic medicine more efficient to produce and improve accessibility.
-
Manufacturing, Supply Chain & Infrastructure2 months agoEngineered genomic attachment sites for site-specific recombinases enable high-efficiency integration in plants and human cells
Nature Biotechnology, Published online: 02 September 2026; doi:10.1038/s41587-026-03294-yDNA recombination in rice is optimized by engineering genomic attachment sites.
-
Manufacturing, Supply Chain & Infrastructure2 months agoIndustrial-scale microbial foods—growth strategies for the next-generation protein market
The question is no longer whether microbial foods can be made. The question now is who can be first to turn them into an industry. KAIST...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
